Dramatic response of refractory sarcoidosis under ruxolitinib in a patient with associated JAK2-mutated polycythemia. Issue 6 (20th December 2018)

• Record Type: Journal Article
• Authors: Rotenberg, Cécile; Besnard, Valérie; Brillet, Pierre-Yves; Giraudier, Stéphane; Nunes, Hilario; Valeyre, Dominique
• Is Part Of: European respiratory journal. Volume 52:Issue 6(2018)
• Publication Date: 2018-12-20
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.01482-2018
• Languages: English
• ISSNs: 0903-1936

Abstract

Sarcoidosis is a systemic disorder of unknown aetiology characterised by the formation of non-caseating epithelioid granulomas in involved organs. Although a spontaneous remission is frequent, up to 28–53% of patients may follow a persistent active course for more than 5 years [1, 2]. Outcome may be severe in a subset of these patients. Sarcoidosis treatment relies on three lines of therapies respectively corticosteroids, immunosuppressive medications and anti-tumour necrosis factor-α (anti-TNF-α) therapy according to severity. Potential role of the JAK-STAT pathway in sarcoidosis http://ow.ly/L8Du30m78XI